Phase 3 Readout~month

Phase 3 Topline: Prospective Phase 3 Multi-center 2-Year Placebo Controlled Double Blind Study to Evaluate the Effica

Indication
Alpha 1-Antitrypsin Deficiency

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Prospective Phase 3 Multi-center 2-Year Placebo Controlled Double Blind Study to Evaluate the Effica — KMDA Phase 3 Readout | BioSniper